CELG-RI

MKT CAP:$164M

Bristol-Myers Squibb Company Ce

Market Cap

$164M

Healthcare·Drug Manufacturers - General·🇺🇸 United States·NYSE

Healthcare·Drug Mfg.·🇺🇸·NYSE

Stock Price

$0.10+$0.02 (+25.52%)

Apr 21, 2026

Company Details

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics...

CEO

Christopher S. Boerner

IPO Date

—

Website

www.bms.com

Key Metrics TTM

Revenue

$22.9B

— YoY

Net Income

$1.7B

EPS (Diluted)

$1.02

Free Cash Flow

$12.8B

Revenue / Share

$13.98

Gross Margin

69.9%

Operating Margin

24.1%

Net Margin

7.5%

FCF Margin

56.1%

P/S

0.0x

P/E

0.1x

Earnings Reports

Q3 2019

Apr 30, 2026

PENDING

FY 2019

Jul 25, 2019

$12.2BEPS $1.93

Q2 2019

Jul 25, 2019

$6.3BEPS $0.87

Q1 2019

Apr 25, 2019

$5.9BEPS $1.04

FY 2017

Feb 13, 2018

$5.4B+3.9%EPS -$1.42

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 16	$5.2B	$3.9B	$1.0B
Q4 17	$5.4B	$3.8B	$754M
Q1 19	$5.9B	$4.1B	$2.0B
Q2 19	$6.3B	$4.3B	$1.7B

Valuation

Quarter	P/S	P/E
Q4 16	—	—
Q4 17	—	—
Q1 19	—	—
Q2 19	0.0x	0.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	$5.3B	$5.0B
Q4 21	$4.1B	$3.7B
Q1 22	$3.8B	$3.6B
Q3 22	$3.7B	$3.4B
Q4 22	$3.3B	$3.0B
Q1 23	$3.0B	$2.7B
Q2 23	$1.9B	$1.6B
Q3 23	$4.8B	$4.4B
Q4 23	$4.3B	$3.9B
Q1 24	$2.8B	$2.5B
Q2 24	$2.3B	$2.1B
Q3 24	$5.6B	$5.3B
Q1 25	$2.0B	$1.7B
Q2 25	$3.9B	$3.6B
Q3 25	$6.3B	$6.0B
Q4 25	$2.0B	$1.6B

Capital Expenditures

Quarter	CapEx
Q3 21	$270M
Q4 21	$320M
Q1 22	$253M
Q3 22	$247M
Q4 22	$346M
Q1 23	$278M
Q2 23	$259M
Q3 23	$342M
Q4 23	$330M
Q1 24	$284M
Q2 24	$262M
Q3 24	$324M
Q1 25	$260M
Q2 25	$361M
Q3 25	$320M
Q4 25	$370M

CapEx

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$142M	—
Q4 21	$133M	—
Q1 22	$107M	—
Q3 22	$115M	—
Q4 22	$119M	—
Q1 23	$122M	—
Q2 23	$137M	—
Q3 23	$132M	—
Q4 23	$127M	—
Q1 24	$810M	—
Q2 24	$125M	—
Q3 24	$129M	—
Q1 25	$144M	—
Q2 25	$137M	—
Q3 25	$139M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 16	$1.4B	$25M	$1.5B
Q4 17	$1.9B	$71M	$1.3B
Q1 19	$1.4B	—	$1.0B
Q2 19	$1.3B	—	$1.1B

Revenue Segments

Quarter	Abilify	Baraclude	Eliquis	Empliciti	Hepatitis C Portfolio	Mature Products And All Other	Opdivo	Orencia	Reyataz	Sprycel	Sustiva Franchise	Yervoy
Q4 16	$31M	$296M	$948M	$47M	$226M	$550M	$1.3B	$625M	$206M	$494M	$246M	$264M
Q4 17	—	$233M	$1.4B	$63M	$59M	$595M	$1.4B	$662M	$143M	$527M	$174M	$269M
Q1 19	—	$141M	$1.9B	$83M	—	$487M	$1.8B	$640M	—	$459M	—	$384M
Q2 19	—	$147M	$2.0B	$91M	—	$481M	$1.8B	$778M	—	$544M	—	$367M

Revenue by Geography

Quarter	Europe	Other Region	Rest Of World	United States
Q1 19	$1.5B	$117M	$874M	$3.4B
Q2 19	$1.5B	$127M	$988M	$3.7B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 16	1.68B	—	—
Q4 17	1.64B	-2.2%	—
Q1 19	1.64B	-0.4%	—
Q2 19	1.64B	0.0%	—

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 16	$209.7K	25K
Q4 17	$229.9K	24K
Q1 19	$254.1K	23K
Q2 19	$269.2K	23K

Revenue / Employee